Retrospective evaluation of demographic data, clinical features and survival of patients with pancreatic cancer

Authors : Halit Kandemir, Yücel Üstündağ

Pages : 147-158

Doi:10.17941/agd.1717035

View : 27 | Download : 25

Publication Date : 2026-02-20

Article Type : Research Paper

Abstract :Background and Aims: This study aimed to evaluate the demographic characteristics, clinical features, and survival outcomes of patients diagnosed with pancreatic cancer. Additionally, patients diagnosed with pancreatic neuroendocrine tumors were included for comparative analysis. Materials and Methods: In this study, we retrospectively reviewed the records of 169 patients diagnosed with pancreatic cancer or pancreatic neuroendocrine tumors between January 1, 2011, and June 1, 2020, at Zonguldak Bülent Ecevit University Health Practice and Research Center. Demographic data, clinical characteristics, overall survival, and progression-free survival were analyzed. Results: Of the 169 patients, 152 (89.9%) had pancreatic cancer and 17 (10.1%) had pancreatic neuroendocrine tumors. The mean age at diagnosis was 60.7 years; 40.8% were female and 59.2% male. Median overall survival and progression-free survival for all patients were 11 and 6 months, respectively. In pancreatic cancer patients, overall survival was 10 months and progression-free survival 6 months, whereas in pancreatic neuroendocrine tumors patients, overall survival and progression-free survival were significantly longer (39 and 30 months, respectively). Eastern Cooperative Oncology Group performance status, body mass index, tumor-node-metastasis stage, surgery, and radiotherapy were significantly associated with overall survival and progression-free survival in both groups. In pancreatic cancer patients only, elevated carbohydrate antigen 19-9 levels and metastases (lymph node, liver, lung, peritoneum) negatively affected overall survival and progression-free survival. Factors such as alcohol/smoking habits, tumor size and location, chemotherapy, and biliary stenting showed no significant impact on survival in either group. Conclusion: Overall survival and progression-free survival were significantly worse in patients with pancreatic cancer compared with those with pancreatic neuroendocrine tumors. Consistent with the literature, advanced tumor–node–metastasis stage, poor ECOG performance status, and the presence of peritoneal metastasis at diagnosis had a statistically significant negative impact on both overall survival and progression-free survival in pancreatic cancer cases. In these patients, the presence of lymph node metastasis at diagnosis and elevated carbohydrate antigen 19-9 levels were found to negatively affect only overall survival. Although some studies have reported that biliary decompression provides an overall survival advantage in patients with pancreatic cancer, our study found no effect of biliary decompression on survival.
Keywords : Pankreas kanseri, erken evre, genel sağ kalım, progresyonsuz sağ kalım.

ORIGINAL ARTICLE URL